# Windlas Biotech (NSE: WINDLAS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/WINDLAS · Pivot · prices to 22 Oct 2026

Windlas Biotech (NSE: WINDLAS) closed at ₹885.70 on 22 Oct 2026, down 0.20% on the day. With a market capitalisation of ₹1,828 Cr, it ranks 1180th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 28.4× trailing earnings, against a return on equity of 11.5% in FY26. Over the past year the share price has fallen 2.2%. Its 52-week range is ₹697.40 (16 Mar 2026) to ₹1,181.90 (7 Sep 2026); the last close is 25.1% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹239 Cr (+17.7% year on year) and net profit ₹16 Cr (−1.8%), on a consolidated basis. Promoters held 63.31% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹885.70 |
| Market cap | ₹1,828 Cr |
| P/E (trailing) | 28.4 |
| ROE | 11.5% (FY26) |
| ROCE | 15.7% (FY26) |
| Debt to equity | 0.05 |
| 52-week high | ₹1,181.90 (7 Sep 2026) |
| 52-week low | ₹697.40 (16 Mar 2026) |
| 1-year return | −2.2% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹239 Cr | +17.7% | ₹16 Cr | −1.8% | ₹7.58 |
| Q3 FY26 | ₹233 Cr | +19.5% | ₹15 Cr | −3.7% | ₹7.12 |
| Q2 FY26 | ₹222 Cr | +18.9% | ₹18 Cr | +13.7% | ₹8.48 |
| Q1 FY26 | ₹210 Cr | +19.9% | ₹18 Cr | +31.0% | ₹8.43 |
| Q4 FY25 | ₹203 Cr | +18.3% | ₹16 Cr | −4.2% | ₹7.77 |
| Q3 FY25 | ₹195 Cr | +20.2% | ₹16 Cr | +3.2% | ₹7.45 |
| Q2 FY25 | ₹187 Cr | +22.5% | ₹16 Cr | +11.6% | ₹7.49 |
| Q1 FY25 | ₹175 Cr | +21.0% | ₹13 Cr | +11.7% | ₹6.47 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹760 Cr | ₹61 Cr |
| FY24 | ₹631 Cr | ₹58 Cr |
| FY23 | ₹513 Cr | ₹43 Cr |
| FY22 | ₹466 Cr | ₹38 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 63.31%
- Foreign institutions: 2.04%
- Domestic institutions: 9.84%
- Non-institutions: 24.80%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Beta Drugs](https://app.pivotnow.in/stock/BETA) | ₹1,773.00 | ₹1,966 Cr | 43.4 | — |
| [Hester Biosciences](https://app.pivotnow.in/stock/HESTERBIO) | ₹2,165.00 | ₹1,842 Cr | 32 | — |
| [Titan Biotech](https://app.pivotnow.in/stock/TITANBIO) | — | ₹1,793 Cr | — | — |
| [Fischer Medical Ventures](https://app.pivotnow.in/stock/FISCHER) | ₹26.21 | ₹1,715 Cr | 58.2 | — |
| [NGL Fine-Chem](https://app.pivotnow.in/stock/NGLFINE) | ₹2,717.20 | ₹1,679 Cr | 34.8 | — |
| [Krsnaa Diagnostics](https://app.pivotnow.in/stock/KRSNAA) | ₹510.75 | ₹1,657 Cr | 16.5 | — |

## Questions and answers

### What is the share price of Windlas Biotech today?

Windlas Biotech (NSE: WINDLAS) last closed at ₹885.70 on 22 Oct 2026. Its 52-week high is ₹1,181.90 and its 52-week low is ₹697.40.

### What is the market cap of Windlas Biotech?

Windlas Biotech's market capitalisation is ₹1,828 Cr (₹1,828 Cr) at the 22 Oct 2026 close, ranking 1180th among the NSE companies Pivot tracks.

### What is the P/E ratio of Windlas Biotech?

Windlas Biotech trades at a trailing P/E of 28.4. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 34.8.

### What is the ROE and ROCE of Windlas Biotech?

Return on equity was 11.5% in FY26 and return on capital employed was 15.7% in FY26 (consolidated figures).

### Is Windlas Biotech a debt-free company?

Windlas Biotech is close to debt-free: its debt-to-equity ratio was 0.05 in FY26.

### What were Windlas Biotech's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Windlas Biotech reported revenue of ₹239 Cr, +17.7% year on year, and net profit of ₹16 Cr, −1.8% year on year.

### How has Windlas Biotech stock performed over the last year?

Windlas Biotech's share price has fallen 2.2% over the past year, +1.8% over three months and −21.6% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Windlas Biotech?

As of 30 Jun 2026: promoters 63.31%, foreign institutions 2.04%, domestic institutions 9.84%, non-institutions 24.80%.

### Who are Windlas Biotech's competitors?

The listed Pharma & Healthcare companies closest to Windlas Biotech by market cap are Beta Drugs, Hester Biosciences, Titan Biotech, Fischer Medical Ventures, NGL Fine-Chem and Krsnaa Diagnostics.

### Is Windlas Biotech a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Windlas Biotech's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on WINDLAS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.